SCHEMBL4168541

SCHEMBL4168541

c1cnc2c(c1)ncn2C1CCNCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.49
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
MAPK14 Q16539 5/20 0.44
MAPK13 O15264 2/20 0.44
MAPK12 P53778 2/20 0.44
MAPK11 Q15759 2/20 0.44
PRKCI P41743 1/20 0.41
SIGMAR1 Q99720 1/20 0.39
PRKD3 O94806 2/20 0.39
MAP4K4 O95819 2/20 0.39
PRKACA P17612 2/20 0.39
CSNK1A1 P48729 2/20 0.39
CSNK1D P48730 2/20 0.39
MINK1 Q8N4C8 2/20 0.39
MAP4K5 Q9Y4K4 2/20 0.39
RIPK2 O43353 1/20 0.39
DYRK3 O43781 1/20 0.39
PRKCG P05129 1/20 0.39
LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3290233 0.78 DRD2 (0.57) JAK2JAK1MAPK14MAPK13MAPK12
Hydrochloric Acid SCHEMBL29398597 0.76 DRD2 (0.56) JAK2JAK1MAPK14MAPK13MAPK12
Hydrochloric Acid SCHEMBL4919274 0.76 DRD2 (0.56) JAK2JAK1MAPK14MAPK13MAPK12
Hydrochloric Acid SCHEMBL7655718 0.76 DRD2 (0.56) JAK2JAK1MAPK14MAPK13MAPK12
SCHEMBL30317222 0.75 MAPK14 (0.41) TP53JAK2JAK1MAPK14MAPK13
SCHEMBL30169464 0.73 ACVR1 (0.52) JAK2JAK1PRKCGCCR5HTR6
SCHEMBL8469729 0.73 ACVR1 (0.52) JAK2JAK1PRKCGCCR5HTR6
SCHEMBL1181760 0.73 TP53 (0.50) TP53CLK4CYP2C9HTR6
Hydrochloric Acid SCHEMBL4915661 0.72 JAK1 (0.52) JAK2JAK1MAPK14MAPK13MAPK12
Hydrochloric Acid SCHEMBL29862952 0.72 JAK1 (0.49) JAK2JAK1MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232093-A1 PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-13 US disclosed
US-20120232093-A1 PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-13 US disclosed
US-20120232093-A1 PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-13 US disclosed
US-8202872-B2 Pyrazole derivatives as sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-06-19 US disclosed
US-8202872-B2 Pyrazole derivatives as sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-06-19 US disclosed
US-8202872-B2 Pyrazole derivatives as sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-06-19 US disclosed
US-20090264442-A1 PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVES, S.A. (ES) 2009-10-22 US disclosed
US-20090264442-A1 PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVES, S.A. (ES) 2009-10-22 US disclosed
US-20090264442-A1 PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVES, S.A. (ES) 2009-10-22 US disclosed
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WYETH (US) 2009-03-12 US disclosed
EP-1994032-A1 PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS Laboratorios del Dr. Esteve S.A. (ES) 2008-11-26 EP disclosed
WO-2007098953-A1 PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-09-07 WO disclosed
EP-1829875-A1 Pyrazole derivatives as sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-09-05 EP disclosed
EP-1829875-A1 Pyrazole derivatives as sigma receptor inhibitors LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069319-A1 IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM WNT1, CTNNB1, WNT3A TP53 538/4885JAK2 453/4885JAK1 985/4885
US-20090264442-A1 PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS SIGMAR1, TMEM97, OPRK1 TP53 4654/4885JAK2 879/4885JAK1 564/4885
US-20120232093-A1 PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS SIGMAR1, TMEM97, OPRK1 TP53 4654/4885JAK2 879/4885JAK1 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.